49 related articles for article (PubMed ID: 19433568)
1. Population pharmacokinetic analysis of fluconazole to predict therapeutic outcome in burn patients with Candida infection.
Han S; Kim J; Yim H; Hur J; Song W; Lee J; Jeon S; Hong T; Woo H; Yim DS
Antimicrob Agents Chemother; 2013 Feb; 57(2):1006-11. PubMed ID: 23254425
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic considerations for antifungal therapy optimisation in the treatment of intra-abdominal candidiasis.
Novy E; Roger C; Roberts JA; Cotta MO
Crit Care; 2023 Nov; 27(1):449. PubMed ID: 37981676
[TBL] [Abstract][Full Text] [Related]
3. Optimal Regimens and Clinical Breakpoint of Avilamycin Against
Huang A; Luo X; Xu Z; Huang L; Wang X; Xie S; Pan Y; Fang S; Liu Z; Yuan Z; Hao H
Front Pharmacol; 2022; 13():769539. PubMed ID: 35281904
[No Abstract] [Full Text] [Related]
4. Can We Improve Antifungal Susceptibility Testing?
Durand C; Maubon D; Cornet M; Wang Y; Aldebert D; Garnaud C
Front Cell Infect Microbiol; 2021; 11():720609. PubMed ID: 34568095
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis.
Garvey EP; Hoekstra WJ; Schotzinger RJ; Sobel JD; Lilly EA; Fidel PL
Antimicrob Agents Chemother; 2015 Sep; 59(9):5567-73. PubMed ID: 26124165
[TBL] [Abstract][Full Text] [Related]
6. Data mining validation of fluconazole breakpoints established by the European Committee on Antimicrobial Susceptibility Testing.
Cuesta I; Bielza C; Larrañaga P; Cuenca-Estrella M; Laguna F; Rodriguez-Pardo D; Almirante B; Pahissa A; Rodríguez-Tudela JL
Antimicrob Agents Chemother; 2009 Jul; 53(7):2949-54. PubMed ID: 19433568
[TBL] [Abstract][Full Text] [Related]
7. Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST).
Cuesta I; Bielza C; Cuenca-Estrella M; Larrañaga P; Rodríguez-Tudela JL
Antimicrob Agents Chemother; 2010 Apr; 54(4):1541-6. PubMed ID: 20124002
[TBL] [Abstract][Full Text] [Related]
8. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
9. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.
Pfaller MA; Diekema DJ; Sheehan DJ
Clin Microbiol Rev; 2006 Apr; 19(2):435-47. PubMed ID: 16614256
[TBL] [Abstract][Full Text] [Related]
10. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia.
Rodríguez-Tudela JL; Almirante B; Rodríguez-Pardo D; Laguna F; Donnelly JP; Mouton JW; Pahissa A; Cuenca-Estrella M
Antimicrob Agents Chemother; 2007 Oct; 51(10):3599-604. PubMed ID: 17646421
[TBL] [Abstract][Full Text] [Related]
11. Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance.
Fernández-Ruiz M; Guinea J; Lora-Pablos D; Zaragoza Ó; Puig-Asensio M; Almirante B; Cuenca-Estrella M; Aguado JM; ;
Clin Microbiol Infect; 2017 Sep; 23(9):672.e1-672.e11. PubMed ID: 28143788
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
